🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The @sloan_kettering Med Onc Fellows refining our clinical trial skills at the AACR ASCO #VailWorkshop18. What an incredible opportunity.

In today's Journal of Clinical Oncology, Bob Li and colleagues report promising clinical responses with a HER2 targeting antibody drug conjugate in HER2 mutant lung cancers. 3% of all cancer patients in the MSK-IMPACT cohort have ERBB2 (HER2) mutant tumors. ascopubs.org/doi/abs/10.120… @sloan_kettering

Bridging China and US together to conquer cancer. Dr. Bob T Li ‘s talk at IASLC Asia is touching and amazing. #msk #lungcancer #iaslc #conquercancer

Most RET fusion+ NSCLCs have low/no PD-L1 expression and low TMB. No response to single-agent/combination IO was seen in our series. Median PFS: 3.4 months. ascopubs.org/doi/10.1200/PO… Michael Offin Marc Ladanyi Gʀᴇɢᴏʀʏ Rɪᴇʟʏ Natasha Rekhtman MD PhD Ryma Benayed Dazhi Liu, Pharm.D, BCOP

Amazing discussion by Robin Guo at #ASCO19 on METex14 altered lung cancers and the role of further investigation of intrinsic and acquired resistance mechanisms to targeted therapy Alexander Drilon MD Natasha Rekhtman MD PhD Marc Ladanyi @sloan_kettering

Great work by Alexander Drilon MD Isabel Preeshagul Robin Guo at #IASLC evaluating response to Cabozantinib beyond the first line in ROS-1 rearranged lung cancers @sloan_kettering

In a new JTO Editor's Choice article, Offin and colleagues present findings from an institutional series of 43 patients with #EGFR, RB1 and TP53 mutations in comparison to 143 EGFR mutant, RB1 and TP53 wild type controls. #LCSM bit.ly/33gy0x1

JTO & JTO CRR And these are my thoughts on this excellent paper bit.ly/2VuixqH

#OncoAlert In Annals of Oncology Risk of radiation pneumonitis high for patients with prior checkpoint inhibitor induced immune-related adverse events. Similar to known exaggerated risk with some autoimmune conditions. #LCSM annalsofoncology.org/article/S0923-…

#OncoAlert Characterization of #EGFR L861Q mutation JTO & JTO CRR IASLC. L861Q was ~ 3% of EGFR mutations (30% had compound mutations, usually in exon 18). Retrospectively, better outcomes with 2nd gen EGFR TKIs compared to 1st or 3rd generation. #LCSM jto.org/article/S1556-…

Super excited and grateful to be a recipient of a LUNGevity Foundation 2022 Career Development Award! Thankful to my amazing team of mentors at Memorial Sloan Kettering Cancer Center. Congratulations are also in order to my colleagues Kristen A. Marrone, MD and Joshua Reuss!

New diffuse pleural mesothelioma #cancerresearch from Michael Offin Triparna Sen (Sen-Lab) Charlie Rudin & co Memorial Sloan Kettering Cancer Center who established patient-derived xenografts which provide insight into the genomic, transcriptomic, and protein landscape of MPM bit.ly/3hLgFZI

A recent review of cases of pericardial mesothelioma at one institution by Michael Offin indicated improved survival for patients who underwent multi-modality treatment (surgery, chemotherapy, radiation) at a center with multi-disciplinary expertise. curemeso.org/2022/12/08/ult…

Great to work with #MarjorieZauderer Michael Offin Memorial Sloan Kettering Cancer Center! 24 pts w/ peritoneal #mesothelioma treated with pembro, ORR 21%, SD 53%, 3 pts w PFS > 2 years. Outcomes numerically better for non-epi histology. Penn Medicine - Abramson Cancer Center Corey Langer #curemeso tinyurl.com/2p8bmwyr